HK1216544A1 - 病毒載體納米膠囊靶向基因治療及其製備 - Google Patents

病毒載體納米膠囊靶向基因治療及其製備

Info

Publication number
HK1216544A1
HK1216544A1 HK16104346.5A HK16104346A HK1216544A1 HK 1216544 A1 HK1216544 A1 HK 1216544A1 HK 16104346 A HK16104346 A HK 16104346A HK 1216544 A1 HK1216544 A1 HK 1216544A1
Authority
HK
Hong Kong
Prior art keywords
nanocapsule
preparation
gene therapy
viral vector
targeting gene
Prior art date
Application number
HK16104346.5A
Other languages
English (en)
Inventor
Yunfeng Lu
Ming Yan
Irvin S Y Chen
Min Liang
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1216544A1 publication Critical patent/HK1216544A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16104346.5A 2012-12-14 2016-04-15 病毒載體納米膠囊靶向基因治療及其製備 HK1216544A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737233P 2012-12-14 2012-12-14
PCT/US2013/075362 WO2014093966A1 (en) 2012-12-14 2013-12-16 Viral vector nanocapsule for targeting gene therapy and its preparation

Publications (1)

Publication Number Publication Date
HK1216544A1 true HK1216544A1 (zh) 2016-11-18

Family

ID=50935028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104346.5A HK1216544A1 (zh) 2012-12-14 2016-04-15 病毒載體納米膠囊靶向基因治療及其製備

Country Status (7)

Country Link
US (2) US10179112B2 (zh)
EP (1) EP2931903B1 (zh)
JP (2) JP6502261B2 (zh)
AU (2) AU2013358922B2 (zh)
CA (1) CA2932542C (zh)
HK (1) HK1216544A1 (zh)
WO (1) WO2014093966A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3223802A4 (en) 2014-11-26 2018-07-04 The Regents of The University of California Stealth nanocapsules for protein delivery
WO2017106380A1 (en) 2015-12-18 2017-06-22 The Regents Of The University Of California Protein nanocapsules with detachable zwitterionic coating for protein delivery
US20200323786A1 (en) * 2016-05-24 2020-10-15 The Regents Of The University Of California Growth-factor nanocapsules with tunable release capability for bone regeneration
GB201708203D0 (en) * 2017-05-22 2017-07-05 Sagetis Biotech Sl Chemical compounds
BR112020001059A2 (pt) 2017-07-18 2020-07-14 Calimmune, Inc. composições e métodos para o tratamento de beta-hemoglobinopatias
EP3740199A2 (en) * 2018-01-17 2020-11-25 aratinga. bio TNP Polymer-encapsulated viral vectors for genetic therapy
KR20210118833A (ko) 2018-12-23 2021-10-01 씨에스엘 베링 엘엘씨 킬 스위치를 갖는 공여 t 세포
AU2021294317A1 (en) 2020-06-26 2023-02-23 Csl Behring Llc Donor T-cells with kill switch

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450153A (en) 1982-09-30 1984-05-22 Phillips Petroleum Company Alcohol removal from blood with alcohol oxidase
US7279318B1 (en) * 1999-06-09 2007-10-09 Hybrid Systems Limited Modification of biological elements
JPWO2004074463A1 (ja) * 2003-02-19 2006-06-01 学校法人早稲田大学 細胞分離用ハイドロゲルおよび細胞の分離方法
US20070009441A1 (en) 2004-07-08 2007-01-11 Molecular Therapeutics, Inc. Biodegradable nanoparticles
WO2006129080A1 (en) 2005-05-31 2006-12-07 The Institute Of Cancer Research: Royal Cancer Hospital Materials and methods for transducing cells with a viral vector
CN101679021B (zh) 2007-03-02 2014-04-30 伊利诺伊大学评议会 药物颗粒送递
US20080312134A1 (en) 2007-06-11 2008-12-18 Thomas Hirt Vesicles for active macromolecule delivery
CN102083462B (zh) * 2007-08-03 2015-02-18 巴斯德研究院 慢病毒基因转移载体及其医学应用
US20090060894A1 (en) 2007-08-27 2009-03-05 John Charin Somberg Treatment to aid in the metabolism of alcohol
WO2009053700A1 (en) * 2007-10-23 2009-04-30 Cancer Research Technology Limited Modification of nucleic acid-containing biological entities
IE20080211A1 (en) 2008-03-20 2009-11-25 Nat Univ Ireland Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
EA201100915A1 (ru) * 2008-12-11 2012-01-30 Сайоксус Терапьютикс Лимитед Модификация нуклеиновокислотных векторов с помощью полимеров, включающих заряженные четвертичные аминогруппы
WO2010139061A1 (en) * 2009-06-02 2010-12-09 Harald Stover Immuno-compatible hydrogel system
US9283194B2 (en) * 2010-04-16 2016-03-15 The Regents Of The University Of California Methods for protease assisted protein delivery
US20140037748A1 (en) 2011-04-15 2014-02-06 The Regents Of The University Of California Redox responsive polymeric nanocapsules for protein delivery
CA2841079A1 (en) 2011-07-06 2013-01-10 Otto O. YANG Oral delivery of enzymes by nanocapsules for targeted metabolism of alcohol or toxic metabolites
US9993440B2 (en) 2011-09-02 2018-06-12 The Regents Of The University Of California Enzyme responsive nanocapsules for protein delivery
AU2013231839B2 (en) 2012-03-16 2017-11-23 The Regents Of The University Of California A novel RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules

Also Published As

Publication number Publication date
CA2932542A1 (en) 2014-06-19
AU2013358922B2 (en) 2019-08-22
JP6502261B2 (ja) 2019-04-17
JP2019135235A (ja) 2019-08-15
EP2931903A4 (en) 2016-07-27
JP2016501895A (ja) 2016-01-21
AU2019268128A1 (en) 2019-12-12
WO2014093966A1 (en) 2014-06-19
EP2931903B1 (en) 2021-07-28
CA2932542C (en) 2023-06-06
US20190046461A1 (en) 2019-02-14
AU2013358922A1 (en) 2015-07-23
US10179112B2 (en) 2019-01-15
EP2931903A1 (en) 2015-10-21
JP6797959B2 (ja) 2020-12-09
US20150320693A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
HK1206782A1 (zh) 基因治療載體的廣泛的基因遞送
HK1249548A1 (zh) 用於無脈絡膜的基因療法的aav載體
HK1216544A1 (zh) 病毒載體納米膠囊靶向基因治療及其製備
HK1212376A1 (zh) 指導的人類基因組改造
EP2839013A4 (en) DISRUPTION-FREE GEN-TARGETING
HK1209340A1 (zh) 信使 的肺遞送
EP2847337A4 (en) PLASMIDS AND VIRAL VECTORS ASSOCIATED WITH ADENOVIRUS
EP2861737A4 (en) GEN TARGETING IN PLANTS THROUGH DNA VIRUSES
EP2877572A4 (en) ONCOLYTIC VIRUS TREATMENT OF RESISTANT TUMORS
EP2714090A4 (en) OBJECTIVE PEPTIDES AND METHOD THEREFOR
GB201110647D0 (en) Delivery of viral agents
SG11201500396TA (en) Tumor vaccination
EP2687204A4 (en) VECTOR FOR PULMONARY ADMINISTRATION, INDUCTION AGENT, AND USES
EP2987504A4 (en) NON-VIRAL GENE DELIVERY SYSTEM FOR TARGETING ADIPOSE CELLS
HRP20181439T1 (hr) Cjepivo protiv modificiranog virusa sendai i vizualizacijski vektor
IL239152A0 (en) Biological mixture inactivated from viruses
SG2014006373A (en) Baculovirus system for the expression of a gene therapy vector
ZA201402071B (en) Vaccine therapy
EP2907876A4 (en) REDUCTION STIMULUS REACTIVE GENETECTOR SYSTEM AND MANUFACTURE AND USE THEREOF
GB201215184D0 (en) Therapeutic virus
EP2792744A4 (en) GENE TARGETING VECTOR AND METHOD OF USE
GB201201397D0 (en) Gene targeting in animals
AU2011903701A0 (en) Risk assessment for viral therapy
GB201208199D0 (en) Inhaler and associated capsule chamber
GB201009217D0 (en) Targeted gene therapy